DDX53 and colonic neoplasm: Complementing this, a synthetic LRP antagonist, RRP‐Dkk1c is developed, which exhibits heightened effectiveness in attenuating Wnt/β‐catenin signaling activity compared to Dkk1, thereby abolishing the formation of CT26‐derived colon cancer xenograft in vivo.